Here are the top 20 largest in CU6's space
Top 20 Radiopharma Companies Based on Market Cap
https://www.pharmashots.com/14882/top-20-radiopharma-companies-based-on-market-cap
Top 20 Radiopharma Companies Based on Market CapShots:Integrating scintigraphy with therapeutics, radiopharmaceutical companies have emerged profoundly in the past few decades. With the growing influence of radiopharmaceutical companies in oncology, the companies hold a firm grasp on the marketWith the expanding acceptance among HCPs, patients, and researchers, radiopharmaceutical companies are estimated to touch the $7.5B threshold by 2026. This year, Novartis has secured the top position with a market cap of $207.65B, followed by Bayer and Lantheus Medical ImagingPharmaShots has compiled a list of the Top 20 Radiopharma Companies developing products as a treatment option, ranked based on their market capMarket Cap: $8.46MFounded Year: 2004Total Employees: ~4Headquarters: Texas, United StatesStock Exchange: OTCMKTSQSam Biosciences is a clinical-stage biotech company focused on developing and commercializing targeted therapeutic radiopharmaceutical products for treating cancer and related diseases. The company's main radiopharma asset includes CycloSam (Samarium-153 DOTMP), a bone-targeting radiopharmaceutical developed by IsoTherapeutics. In Aug’21, the US FDA cleared QSam’s IND application for CycloSam. The company expects to commence P-I clinical trials on metastatic and pediatric primary bone cancer patients. Market Cap: $8.57MFounded Year: 2009Total Employees: ~40Headquarters: Oslo, NorwayStock Exchange: OSENordic Nanovector is a biotech company committed to developing and commercializing antibody-radionuclide conjugates to address significant unmet medical needs. The company's lead asset includes Betalutin, a novel CD37-targeting antibody-radionuclide-conjugate developed to treat patients with NHL. Other radiotherapies under the company's pipeline include Humalutin and Alpha37. Nordic is advancing the development of CD37-targeted therapies for hematological cancers and immune diseases. Market Cap: $10.67MFounded Year: 2009Total Employees: ~410Headquarters: Colorado, United StatesStock Exchange: OTCMKTSClovis Oncology is a biopharma company that develops and delivers anti-cancer agents to the US, EU, and other international markets. FAP-2286 (labeled with lutetium-177), a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP), is the company’s lead asset amongst radiopharma products. In Sep’19, Clovis entered into a global licensing and collaboration agreement with 3B Pharmaceuticals to develop FAP-2286. In Jun’21, the company initiated the evaluation of FAP-2286 in a P-I/II clinical trial (LuMIERE) following the US FDA’s IND clearance. Market Cap: $15.26MFounded Year: 1996Total Employees: ~10Headquarters: New Jersey, United StatesStock Exchange: NASDAQCellectar is a late-stage clinical biopharma company obligated to the development and commercialization of products for the treatment of cancer. The company is utilizing its Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs targeting cancer cells to provide safe and effective results. Cellectar’s lead PDC therapeutic includes Iopofosine, a small-molecule PDC that provides targeted delivery of iodine-131 directly to cancer cells. On Aug’21, Cellectar entered into a commercial manufacturing and supply agreement with Evergreen Theragnostics for Iopofosine I-131. Market Cap: $21.06MFounded Year: 2021Total Employees: ~10Headquarters: Victoria, AustraliaStock Exchange: ASXRadiopharm Theranostics is a biotech company focused on developing radiopharmaceuticals for diagnosing and treating diseases with high unmet medical needs. DUNP19, a dual-action LRRC15-targeted monoclonal antibody, is the company’s lead asset. In Sep’21, the US FDA granted DUNP19 an ODD for Osteosarcoma. In addition to developing DUNP19, Radiopharm is also evaluating Cu64 and Lu177 isotopes under preclinical studies. Market Cap: $25.97MFounded Year: 1991Total Employees: ~180Headquarters: Beijing, ChinaStock Exchange: NASDAQCASI Pharmaceuticals is a biopharma company dedicated to developing and commercializing therapeutic and pharmaceutical products worldwide, including in the US and China. The company develops Zevalin under its radiopharmaceutical segment. CASI Pharmaceuticals received the rights and exclusive license to Zevalin from Acrotech Biopharma. Zevalin is a CD20-directed radiotherapeutic antibody, and its therapeutic regimen consists of rituximab and Yttrium-90 (Y-90) radiolabeled Zevalin. Market Cap: $29.30MFounded Year: 2001Total Employees: ~20Headquarters: Tokyo, JapanStock Exchange: TYOPerseus Proteomics is a Japanese biotech company focused on developing antibodies by utilizing antibody technology to provide treatment options to patients worldwide. The company is developing PPMX-T002, an anti-cancer drug with an antibody targeting CDH3 connected with a radioisotope yttrium 90 (90Y). Perseus has been discussing the collaborative development of PPMX-T002 with various RI medical drug-developing companies, including PeptiDream and its subsidiary PDRAdhiopharma. Market Cap: $82.80MFounded Year: 2001Total Employees: ~70Headquarters: Kawasaki, JapanStock Exchange: TYOOncoTherapy Science is a biotech company focused on developing novel molecular-targeted anti-cancer drugs using its own technologies. Under its cancer therapy products, the company develops low molecular drugs, antibody drugs, cancer peptide vaccines, and diagnostic medicines. Under its radiopharmaceutical segment, OncoTherapy is developing OTSA101, an anti-FZD10 antibody that specifically binds to FZD10 in cancer cells. In mouse xenograft models, the radioactive isotope-conjugated OTSA101 showed strong anti-cancer activity by tumor-specific irradiation. Market Cap: $101.87MFounded Year: 2010Total Employees: ~200Headquarters: Eveleigh, AustraliaStock Exchange: ASXClarity Pharma is a clinical-stage radiopharma company obligated to develop radiopharmaceuticals for treating severe diseases. The company has expertise in developing Targeted Copper Theranostics based on its SAR Technology Platform for treating children and adults with cancer. Clarity has a diverse range of products, including Sartate (in P-I/IIa for neuroblastoma) and SAR-Bombesin (in P-II for breast and prostate cancer). The company develops products targeting multiple indications, including orphan indications. Market Cap: $197.92MFounded Year: 1897Total Employees: ~750Headquarters: Seoul, KoreaStock Exchange: KRXDong Wha Pharmaceutical is a Korean pharma company focused on developing over-the-counter drugs for therapeutic areas, including antipyretics, analgesics, and antibiotics for cardiovascular, dermatological, and alimentary ailments. Under its radiopharma division, the company is developing Milican (DW-166HC) injections for hepatocellular carcinoma and hemophiliac arthritis. Market Cap: $229.63MFounded Year: 2014Total Employees: ~90Headquarters: Ontario, CanadaStock Exchange: NASDAQFusion Pharmaceuticals is a clinical-stage radiopharma company dedicated to developing radiopharmaceuticals as precision medicines. The company has developed a Targeted Alpha Therapies (TAT) platform to connect alpha particle emitting isotopes to various targeting molecules to deliver alpha particle payload to tumors selectively. Fusion's lead assets include [225Ac]-FPI-1434 (FPI-1434), developed by combing an antibody, IGF-1R, with its Fast-Clear linked technology to create a TAT for utility across multiple tumor types. In May’21, Fusion entered a clinical collaboration with Merck to evaluate FPI-1434 in combination with Keytruda in patients with solid tumors expressing IGF-1R. Market Cap: $363.39MFounded Year: 2000Total Employees: ~30Headquarters: New York, United StatesStock Exchange: NYSE AMERICANActinium Pharmaceuticals is a clinical-stage biopharma company dedicated to developing targeted radiotherapies. It utilizes its proprietary platform technology and deep understanding of radiobiology to provide treatment options for patients with unmet needs. The company develops targeted radiotherapies by combining the cell-killing ability of radiation through a radioisotope payload with a targeting agent, like a monoclonal antibody, to deliver radiation to targeted cells. Iomab-B is Actinium's lead asset and targeted conditioning agent comprising an anti-CD45 monoclonal antibody and the radioisotope Iodine-131 (I-131). The company is evaluating Iomab-B in a P-III clinical trial (SIERRA) in patients with relapsed or refractory acute myeloid leukemia (AML). Market Cap: $599.17MFounded Year: 1978Total Employees: ~6000Headquarters: Uttar Pradesh, IndiaStock Exchange: NSEJubilant Pharma is a pharmaceutical company obligated to deliver its products and services to patients worldwide. The company has classified its business into segments, including specialty pharmaceuticals, comprising radiopharmaceuticals, contract manufacturing of sterile injectables and non-sterile products, allergy therapy products, generics & APIs containing solid dosage formulations, and active pharmaceutical ingredients. Under its radiopharma segment, the company's lead asset is Hicon, a radioactive therapeutic agent indicated for hyperthyroidism and some cases of thyroid carcinoma. Market Cap: $770.15MFounded Year: 2019Total Employees: ~70Headquarters: Indiana, United StatesStock Exchange: NASDAQPOINT Biopharma is a clinical-stage pharma company focused on the development and commercialization of radioligand therapies for cancer. It has expertise in radioisotopes, including Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The company's late-stage prostate cancer treatment assets consist of 177Lu-based radiopharmaceuticals, including PNT2002. In Sep’21, POINT initiated a P-III clinical trial (SPLASH) evaluating PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand, for treating patients with mCRPC. Market Cap: $927.56MFounded Year: 1951Total Employees: ~350Headquarters: Istanbul, TurkeyStock Exchange: ISTEczacıbaşı-Monrol is a developer of nuclear medicines and a global supplier of cGMP radiopharmaceutical products obligated to diagnose and treat indications under therapy areas, including Oncology. The company's radiopharma section includes Lutetium (177Lu), developed for treating prostate cancer and neuroendocrine tumors. In Nov’21, Eczacıbaşı-Monrol entered into a clinical supply agreement with Molecular Targeting Technologies (MTTI) for Lutetium (177Lu). Market Cap: $1.33BFounded Year: 2015Total Employees: ~160Headquarters: Melbourne, AustraliaStock Exchange: ASXTelix is a clinical-stage biopharma company dedicated to the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, including TLX591 (177Lu–rosopatamab), TLX592 (225Ac–RADmAb), TLX250 (177Lu–girentuximab), TLX101 (131I-IPA), and TLX66 (90Y-besilesomab). The company’s radiopharma pipeline is focused on indications including Prostate, Kidney, Brain, Blood, and Bone marrow cancers. In 2021, Telix generated total revenue of $7.59M from the sales of its radiopharma products. Market Cap: $1.82BFounded Year: 2006Total Employees: ~200Headquarters: Kanagawa, JapanStock Exchange: TYOPeptiDream is a biopharma company based in Japan, obligated to discover and develop highly functional peptide therapeutics to address unmet medical needs and improve quality of life. On Sep’21, PeptiDream acquired all the outstanding shares of a newly established company (shares of Fujifilm Toyama Chemical will be transferred). Through this acquisition, PeptiDream has brought eight undisclosed radiopharma therapeutic products under its umbrella for treating Thyroid, Non-Hodgkin's Lymphoma, and Pheochromocytoma/ Paraganglioma. Market Cap: $4.12BFounded Year: 1956Total Employees: ~610Headquarters: Massachusetts, United StatesStock Exchange: NASDAQLantheus Medical is an American healthcare company focused on developing imaging diagnostics, targeted therapeutics, and artificial intelligence solutions to find, fight, and follow severe conditions. The company has classified its products into three broad categories: precision diagnostics, radiopharmaceutical oncology, and strategic partnerships. Under its radiopharma section, Lantheus provides radiopharmaceutical oncology diagnostics and therapeutics, including Azedra (iobenguane I 131), approved for locally advanced or metastatic pheochromocytoma or paraganglioma. In 2021, the company’s radiopharmaceutical oncology division contributed $48.89M to the total revenue. Market Cap: $62.83BFounded Year: 1863Total Employees: ~99,600Headquarters: Leverkusen, GermanyStock Exchange: ETRBayer is a multinational biopharma company focused on developing and commercializing products under Oncology, Cardiovascular, and kidney diseases. The company’s radioactive therapeutic agent, Xofigo, is indicated for patients with castration-resistant prostate cancer, symptomatic bone metastases, and no known visceral metastatic disease. Xofigo is being evaluated in a P-IV clinical trial (RADIANT) in response to the EC's request for a P-IV randomized study to characterize the product's efficacy and safety. In 2021, Xofigo generated a sale of $75.08M. Market Cap: $207.65BFounded Year: 1996Total Employees: ~101,700Headquarters: Basel, SwitzerlandStock Exchange: SWXNovartis is a multinational pharma company based in Switzerland focused on providing treatment options for diseases under Oncology, Hepatology, Immunology, Dermatology, Musculoskeletal Diseases, Neuroscience, and Ophthalmology. Novartis' Endocyte expanded its radiopharma division by adding Pluvicto (177Lu-PSMA-617) to its pipeline by acquiring the global rights for its development and commercialization from ABX GmbH in Oct’17. Pluvicto is a radioligand therapeutic targeting the PSMA in prostate cancer patients. Additionally, In Jun’21, Novartis received the BTD from the US FDA for Pluvicto based on the data from P-III clinical trial (VISION).Sources:Annual reportsSEC FilingsPress releasesCompany websitesMarket Cap Source: Google finance (17th Feb 2023)Currency Conversion: X-Rates (17th Feb 2023)Note:All market caps were marked on 17th Feb 2023
(20min delay)